27.25
-0.30 (-1.09%)
| Penutupan Terdahulu | 27.55 |
| Jumlah Dagangan | 77,784 |
| Harga / Buku (P/B) | 2.01 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -9,701.19% |
| EPS Cair (TTM) | -4.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.01% |
| Nisbah Semasa (MRQ) | 21.03 |
| Aliran Tunai Operasi (OCF TTM) | -69.73 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -40.39 M |
| Pulangan Atas Aset (ROA TTM) | -21.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Neurogene Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.2 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 3.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.36 |
|
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.28% |
| % Dimiliki oleh Institusi | 115.82% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |